Celerion Gb Limited

Celerion offers specialized clinical research solutions and bioanalytical services, focusing on early phase drug development to assist pharmaceutical companies in making informed decisions throughout the drug development lifecycle. Celerion Gb Limited, founded in 2010, specializes in early phase clinical research and bioanalytical services aimed at pharmaceutical firms. The company is headquartered in Lincoln, Nebraska, USA, and led by CEO Susan Thornton, who has extensive experience in the life sciences industry. Celerion operates globally, serving markets in North America, Europe, and Asia.

Celerion specializes in providing clinical research solutions and bioanalytical services, focusing primarily on early phase drug development. Their core offerings include comprehensive studies that assess pharmacokinetics (PK), pharmacodynamics (PD), bioanalytical sciences, and clinical trial design, all tailored to meet the specific needs of pharmaceutical companies. The company leverages advanced technologies and methodologies to deliver timely and reliable data, facilitating informed decision-making throughout the drug development lifecycle. Celerion’s clientele consists of pharmaceutical and biotechnology firms that rely on their expertise to navigate the complexities of clinical trials.

Geographically, Celerion serves markets in North America, Europe, and Asia, ensuring access to diverse patient populations and regulatory environments necessary for comprehensive study execution. Celerion generates revenue through a B2B model, providing services directly to pharmaceutical and biotechnology companies engaged in drug development. The transaction structure typically involves service agreements where clients contract Celerion for specific studies or phases of research, such as early phase clinical trials or bioanalytical testing. These contracts are often structured around milestone payments, which align with the completion of defined project phases or deliverables.

Celerion's flagship services, such as their proprietary ClinQuick® and Celexus® offerings, are integral to their revenue streams. The company’s pricing strategies are determined based on the complexity and scope of the services rendered, ensuring that clients receive tailored solutions that address their unique research requirements.